Samarth Kulkarni Sells 6,967 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 6,967 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $52.58, for a total transaction of $366,324.86. Following the completion of the sale, the chief executive officer directly owned 226,106 shares of the company’s stock, valued at $11,888,653.48. The trade was a 2.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total transaction of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Stock Down 2.2%

CRISPR Therapeutics stock traded down $1.18 during mid-day trading on Friday, hitting $53.46. The company’s stock had a trading volume of 1,297,432 shares, compared to its average volume of 1,744,686. The stock has a market capitalization of $5.13 billion, a P/E ratio of -8.20 and a beta of 1.72. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The stock’s fifty day moving average price is $53.90 and its two-hundred day moving average price is $57.27.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The company had revenue of $0.86 million for the quarter, compared to the consensus estimate of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business’s revenue was down 97.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.01) earnings per share. Equities analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on CRSP shares. TD Cowen raised their target price on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Citigroup reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday. Wedbush cut their target price on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 5th. Bank of America reduced their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Finally, Citizens Jmp lowered their price target on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a report on Friday, January 30th. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $64.24.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently made changes to their positions in the company. Mcguire Capital Advisors Inc. bought a new position in CRISPR Therapeutics during the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at $26,000. Optiver Holding B.V. raised its holdings in shares of CRISPR Therapeutics by 71.4% during the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after purchasing an additional 210 shares in the last quarter. Thompson Investment Management Inc. acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at $33,000. Finally, Strategic Advocates LLC bought a new stake in CRISPR Therapeutics in the third quarter worth $34,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.